DUSA Bought by Indian Pharma, Oracle Purchases Instantis: Merger and Acquistions Update

Shares of the dermatology firm DUSA Pharmaceuticals (NASDAQ:DUSA) go through the roof after it agrees to be purchased by India’s Sun Pharma for $8 per share, taking the transaction to a total cash amount of around $230 million. The share price marks a 38 percent bonus to DUSA’s Wednesday close. The company develops and sells the Levulan photodynamic therapy platform for the face and scalp.

Oracle Corporation (NASDAQ:ORCL) acquires Instantis, which develops on-premise non-cloud portfolio project management software which will be joined with the buyer’s Primavera and cloud-based Fusion project management applications. In July, Oracle purchased the cloud project management company Skire.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Shares of Whiting Petroleum Corporation (NYSE:WLL) pull back from an early super-spike on rumors that Statoil (NYSE:STO) had bid $65/share for the firm. However, Benzinga sunsequently reported that Statoil was denying the rumor, which led to the post-spike fall. In mid-afternoon trading, Whiting shares have still moved up from Wednesday.

Don’t Miss: Oracle Reaches for the Clouds With This Acquisition.


To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Premium Newsletters

Stock Investor Cheat Sheet

Stock Investor Cheat Sheet®

The ultimate Cheat Sheet for finding winning stock picks.
Learn More

Gold & Silver Newsletter

Gold & Silver

Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More

Commodities Premium Newsletter

Commodities Premium

There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more

ETF Investing

ETF Investing

At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business